Related Experiment Video
Updated: Apr 27, 2026

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
Published on: April 10, 2015
Ruthenium complexes as NO donors for vascular relaxation induction
Renata Galvão de Lima1, Bruno Rodrigues Silva2, Roberto Santana da Silva3
1Faculdade de Ciências Integradas do Pontal, Universidade Federal de Uberlândia, Ituiutaba 38304-402, MG, Brazil. renatagalvao@pontal.ufu.br.
Ruthenium-derived nitric oxide (NO) donors show potential for hypertension treatment. These compounds release NO through reduction or light, impacting vasodilation and arterial pressure via sGC and potassium channels.
Area of Science:
- Inorganic Chemistry
- Pharmacology
- Cardiovascular Physiology
Background:
- Nitric oxide (NO) donors are crucial for vasodilation and hypertension management.
- NO plays a vital role in regulating vascular tone and arterial pressure.
- Pharmacological strategies utilizing NO donors offer an alternative for hypertension treatment.
Purpose of the Study:
- To review the physicochemical properties of ruthenium-derived NO donor complexes.
- To highlight complexes synthesized in our group over the past decade.
- To discuss the vasodilation and arterial pressure effects of these ruthenium complexes.
Main Methods:
- Focus on ruthenium complexes releasing NO via reduction and light stimulation.
- Analysis of structure-activity relationships for vascular effects.
- Discussion of NO targets: soluble guanylyl cyclase (sGC) and potassium channels.
Main Results:
- Ruthenium complexes demonstrate controlled NO release mechanisms (reduction and light).
- These complexes effectively induce vasodilation and control arterial pressure.
- The chemical structure of ruthenium complexes is critical for their vascular activity.
Conclusions:
- Ruthenium-derived NO donors represent a promising class of compounds for cardiovascular applications.
- Understanding the chemical structure is key to optimizing NO release and therapeutic effects.
- These inorganic compounds offer a novel pharmacological approach to managing hypertension.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Vasodilators
Complexation Equilibria: The Chelate Effect
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3

